menu
    • menu
    [{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"MyPharma2Go Corporation","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Partnership","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Dermatology","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ MyPharma2Go Corporation","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ MyPharma2Go Corporation"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Designs for Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Designs for Health","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Designs for Health"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Neurology","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"||NAD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"||NAD","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Oncology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ChromaDex, Inc \/ Undisclosed"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"ChromaDex, Inc \/ ChromaDex, Inc"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ ChromaDex, Inc","highestDevelopmentStatusID":"1","companyTruncated":"ChromaDex, Inc \/ ChromaDex, Inc"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Sinopharm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ChromaDex, Inc \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ ChromaDex, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by ChromaDex, Inc

    Menu

    ChromaDex, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Nutraceuticals Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

                            Details : Niagen is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            April 09, 2025

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Nutraceuticals Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex's NRC Gets FDA ODD and RPD for Ataxia Telangiectasia

                            Details : Niagen (nicotinamide riboside chloride) is an oral supplement which significantly increases NAD+ levels, it is being investigated in Ataxia Telangiectasia.

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 07, 2024

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+)

                            Details : Niagen is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            August 22, 2023

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Recipient : Charite University, Berlin, Germany

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Fea...

                            Details : Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 31, 2023

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Rib...

                            Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide R...

                            Details : Tru Niagen (nicotinamide riboside) demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 27, 2022

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : MyPharma2Go Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Ni...

                            Details : The cross-border distribution strategy allows for Tru Niagen® (nicotinamide riboside) 300mg 30 count bottles, Tru Niagen® 300mg 90 count bottles and Tru Niagen® 300mg 30 count Stickpacks to be purchased by consumers looking to age healthier.

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            September 01, 2022

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : MyPharma2Go Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Recipient : Sinopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland Chi...

                            Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.

                            Product Name : Tru Niagen

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 10, 2022

                            Lead Product(s) : Nicotinamide Riboside

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Recipient : Sinopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex Launches Tru Niagen® Immune, Further Expanding Innovative Product Portfolio

                            Details : Tru Niagen Immune, is a combination of ingredient Niagen (nicotinamide riboside), and Theracurmin (curcumin) is first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells.

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            April 06, 2022

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            ChromaDex, Inc

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ChromaDex Announces Issuance of Additional New U.S. Continuation Patent, Further Protecting Future Innovations

                            Details : A newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen (nicotinamide riboside) ingredient and other nicotinamide adenine dinucleotide (NAD) precursors.

                            Product Name : Niagen

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 16, 2022

                            Lead Product(s) : Nicotinamide Riboside Chloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth